High Dose Infliximab in the Treatment of Refractory Uveitis : Does Dose Matter?

Abstract EN

Background.

Infliximab (INF) has been shown to be beneficial in treating refractory uveitis, however, no data exist on optimal dosing and the efficacy of higher dosing.

Objectives.

To compare the efficacy of low-dose (LD) (<10 mg/kg), moderate-dose (MD) (≥10–15 mg/kg), and high-dose (HD) INF (≥15–20 mg/kg) in the treatment of uveitis.

Methods.

Retrospective chart review children with uveitis diagnosed at Childrens Hospital Los Angeles and Millers Children’s Hospital, CA, USA.

Results.

Of the 34 INF-treated children, 6 patients received LD, 19 received MD, and 9 received HD.

Average disease duration prior to therapy was 10.6, 24.6, and 37.1 months each group, respectively.

Topical steroids were discontinued after an average of 3 months, 9.5 months, and 10.2 months in the LD, MD, and HD groups, respectively.

We found that 66% of patients receiving LD, 42% of MD, and 66% receiving HD INF failed therapy and required either dose escalation or alternate medication for disease control.

Conclusions.

INF is beneficial in the treatment of uveitis, and dose escalation up to 4 times above the approved dose is often necessary to achieve disease control in patients with uveitis.

Doses < 10 mg/kg every 4 weeks may not be sufficient to control disease.